GH1 and Prader-Willi syndrome: Growth hormone treatment was associated with a reduced risk of thrombosis in PWS, and may be due to a lower frequency of obese-related or comorbid illnesses, known to contribute to blood clotting events in the general population, and impacted positively by the treatment.